Evidence map›Paper›PMID 39506432›Full record

ArticleAdvanced healthcare materials2025

A Pro-Angiogenic Immunoprotective Membrane for Cell Therapies.

Huifeng Wang, Chongwen Duan, Ruyue Luo, Yugang Liu, Ophelia Tong, Julia Demski, Jonathan Rivnay, Guillermo A Ameer

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huifeng WangDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Chongwen DuanDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Ruyue LuoDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Yugang LiuDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Ophelia TongDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Julia DemskiDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Jonathan RivnayDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.
Guillermo A AmeerDepartment of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA.ORCID 0000-0001-6023-048X

Funding

Defense Sciences Office, DARPA FA8650-21-1-7119
6 · The paper itself

Abstract

Immunoisolation strategies that rely on porous membranes play an important role in cell transplantation therapies to protect cells from the host's immune system. These membranes must possess immunoprotective properties while facilitating the transport of nutrients and cell products to maintain the functional integrity of encapsulated cells. An easy and scalable process is described to fabricate a dual function porous polymeric membrane that shields cells against immune cell attack and promotes vascularization to address the nutritional and oxygen requirements of transplanted cells. The fabrication process results in a membrane cross-section with a gradient of nanopores to micropores that support cell immunoisolation and interfacial vascularization requirements, respectively. The membranes demonstrate excellent cell compatibility and effectively prevent T cell transmigration without compromising glucose diffusion and oxygen permeability. In a murine subcutaneous implantation model, membranes are stable for 60 days and exhibit significantly reduced fibrous capsules, with enhanced vascularization near the membrane. These porous polymeric membranes can potentially be used as pro-angiogenic immunoprotective membranes for cell transplantation applications where maximizing cell viability and function is of critical importance.

Indexed as

Membranes, ArtificialAnimalsCell- and Tissue-Based TherapyHumansMiceNeovascularization, PhysiologicPolymersPorosityT-LymphocytesMembranes, ArtificialPolymerscell‐based therapyImmunoisolationporous membranevascularization

Identifiers

PMID39506432
PMCPMC11694084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.